Science

Hope Rugo: Congratulations to Laura Huppert on the multicenter study of sequential ADC use in HER2-low MBC

Hope Rugo and Laura Huppert

Apr 20, 2025, 19:09

Hope Rugo: Congratulations to Laura Huppert on the multicenter study of sequential ADC use in HER2-low MBC

Hope Rugo, Professor of Medicine at the University of California, San Francisco, shared a post on X by Laura Huppert, Assistant Professor at the University of California, San Francisco, adding:

“Congratulations Laura Huppert!

Truly an honor to work with you!”

Quoting Laura Huppert‘s post:

“Excited to share our multicenter retrospective cohort study of ADC sequencing is now published in NPJ Breast!

Thanks to our co-authors for this great team effort!”

Hope Rugo

Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)

Authors: Laura Huppert, Hope Rugo et al.

Hope Rugo

Learn more about HER-2 low breast cancer on OncoDaily.

ADC Ana Sandoval Angelina Raimonde Anne Blaes cancer Dame Idossa Hope Rugo Hope S. Rugo Jenna Hoppenworth Jo Chien Karthik V. Giridhar Kelly Blum Laura A. Huppert Laura Huppert Laura Quintal Lauren Carcas Manmeet Ahluwalia MBC metastatic breast cancer Mi-Ok Kim Michelle Melisko Naomi Dempsey Natasha Harpalani NPJ Breast OncoDaily Oncology Reshma Mahtani Ruta Rao Samantha Fisch Sarah Premji Saya Jacob

Where to Study to Become ASCO President: 2025 Institutional Rankings

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

Dr. Don Dizon and Dr. Nathan Pennell Reflect on the Evolution of the ASCO Educational Book

April is Head and Neck Cancer Awareness Month